D. Juric

发表

High-resolution genome-wide mapping of genetic alterations in human glial brain tumors.

L. Recht, H. Vogel, M. Bredel, 2005, Cancer research.

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

B. Taylor, M. Berger, A. Drilon, 2018, Nature.

Convergent loss of PTEN leads to clinical resistance to a PI3Kα inhibitor

Obi L. Griffith, Malachi Griffith, Benjamin J. Ainscough, 2014, Nature.

Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas.

Dejan Juric, Markus Bredel, L. Recht, 2005, Cancer research.

Abstract B218: Drug-drug interaction assessment of GDC-0032, a beta-sparing inhibitor of phosphoinositide 3-kinase (PI3K), using midazolam, a sensitive CYP3A4 substrate.

J. Baselga, D. Juric, J. Infante, 2013 .

Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome

R. Aharonov, A. Schäffer, E. Ruppin, 2022, bioRxiv.

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

J. Berlin, A. Bardia, D. Juric, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2− Metastatic Breast Cancer

E. Winer, M. Berger, L. Cantley, 2016, Clinical Cancer Research.

Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors.

J. Baselga, D. Juric, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer: A Phase 1b Clinical Trial

J. Baselga, H. Rugo, D. Juric, 2019, JAMA oncology.

Sacituzumab Govitecan in Previously Treated Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Final Results from a Phase 1/2, Single-Arm, Basket Trial.

A. Bardia, D. Juric, Q. Hong, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.

P. Neven, H. Rugo, Yeon-Hee Park, 2021, The Lancet. Oncology.

Alpelisib Plus Fulvestrant for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: Final Overall Survival Results From SOLAR-1.

H. Rugo, H. Iwata, D. Juric, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Time Course and Management of Key Adverse Events During the Randomized Phase 3 SOLAR-1 Study of PI3K Inhibitor Alpelisib Plus Fulvestrant in Patients With HR-Positive Advanced Breast Cancer.

H. Rugo, H. Iwata, D. Juric, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase 1 dose-escalation study of anti-HER3 monoclonal antibody LJM716 in combination with trastuzumab in patients with HER2-overexpressing metastatic breast or gastric cancer.

J. Baselga, D. Juric, J. Schellens, 2014 .

Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer

A. Iafrate, A. Niemierko, A. Bardia, 2021, Clinical Cancer Research.

FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer

A. Iafrate, A. Niemierko, D. Sgroi, 2019, Clinical Cancer Research.

Integrated high-resolution genome-wide analysis of gene dosage and gene expression in human brain tumors.

M. Bredel, C. Bredel, D. Juric, 2007, Methods in molecular biology.

Abstract GS3-08: Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLAR-1 trial

H. Iwata, D. Juric, S. Loibl, 2019, General Session Abstracts.

Severe Lactic Acidosis Complicated by Insulin-Resistant Hyperosmolar Hyperglycemic Syndrome in a Patient With Metastatic Breast Cancer Undergoing AKT-Inhibitor Therapy.

A. Bardia, D. Juric, D. Wexler, 2022, JCO precision oncology.

LBA18 Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC)

H. Iwata, D. Juric, S. Loibl, 2020 .

Temporal and spatial heterogeneity of host response to SARS-CoV-2 pulmonary infection

Linda T. Nieman, N. Hacohen, M. Rivera, 2020, Nature Communications.

Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis

A. Giobbie-Hurder, S. Carter, D. Cahill, 2021, Nature Communications.

Cancer Cell Profiling by Barcoding Allows Multiplexed Protein Analysis in Fine-Needle Aspirates

Ralph Weissleder, Dejan Juric, Vanessa M. Peterson, 2014, Science Translational Medicine.

Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer

J. Nemunaitis, D. Juric, R. Kurzrock, 2021, Journal of Hematology & Oncology.

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

J. Berlin, A. Bardia, D. Juric, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer

A. Villani, R. Sullivan, G. Boland, 2021, Journal for ImmunoTherapy of Cancer.

Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome

R. Aharonov, A. Schäffer, E. Ruppin, 2022, bioRxiv.

EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma.

Patricia Greninger, C. Benes, D. Juric, 2022, Cancer discovery.

Gene expression profiling differentiates germ cell tumors from other cancers and defines subtype-specific signatures.

Yan Wang, Robert Tibshirani, Dejan Juric, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial.

H. Rugo, H. Iwata, D. Juric, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.

A. Richardson, J. Baselga, G. Shapiro, 2016, Cell reports.

The Clinical Landscape of Cell-Free DNA Alterations in 1,671 Patients with Advanced Biliary Tract Cancer.

D. Juric, A. Zhu, J. Lennerz, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract LB-65: Towards defining the genetic framework for clinical response to treatment with BYL719, a PI3Kalpha-specific inhibitor.

J. Lehár, L. Garraway, P. Stephens, 2013 .

Abstract PD5-2: Ph1b study of the PI3K inhibitor taselisib (GDC-0032) in combination with letrozole in patients with hormone receptor-positive advanced breast cancer

E. Winer, J. Baselga, T. Wilson, 2015 .

Abstract LB-64: GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase Ia dose escalation study.

J. Baselga, T. Wilson, D. Juric, 2013 .

Abstract P6-10-07: Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients withPIK3CAmutant advanced solid tumors: preliminary efficacy and safety in patients withPIK3CAmutant ER-positive (ER+) metastatic breast cancer (MBC)

J. Baselga, D. Juric, A. González-Angulo, 2012 .

Abstract P5-19-24: Phase Ib/II study of LEE011 and BYL719 and letrozole in ER+, HER2– breast cancer: Safety, preliminary efficacy and molecular analysis

D. Juric, M. Campone, P. Munster, 2015 .

Phase lb study of LEE011 and BYL719 in combination with letrozole in estrogen receptor-positive, HER2-negative breast cancer (ER+, HER2− BC).

D. Juric, P. Munster, C. Franklin, 2014 .

Aortic Cellular Diversity and Quantitative Genome-Wide Association Study Trait Prioritization Through Single-Nuclear RNA Sequencing of the Aneurysmal Human Aorta

P. Ellinor, E. Isselbacher, D. Juric, 2022, Arteriosclerosis, thrombosis, and vascular biology.

The glutathione S-transferase Gstt1 is a robust driver of survival and dissemination in metastases

Hyo Min Cho, G. Wojtkiewicz, R. Sadreyev, 2022, bioRxiv.

Single-cell barcode analysis provides a rapid readout of cellular signaling pathways in clinical specimens

R. Weissleder, D. Juric, Jonathan C. T. Carlson, 2018, Nature Communications.

Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome

R. Aharonov, A. Schäffer, E. Ruppin, 2022, bioRxiv.

Ph IB study of LEE011 and BYL719 in combination with letrozole in ER+, HER2- breast cancer.

D. Juric, M. Campone, I. Mayer, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

451PDPHASE I STUDY OF THE PI3Kα INHIBITOR BYL719, AS A SINGLE AGENT IN PATIENTS WITH ADVANCED SOLID TUMORS (AST).

J. Berlin, J. Baselga, H. Rugo, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study

J. Berlin, J. Baselga, D. Juric, 2012 .

Detection of microsatellite instability high (MSI-H) status by targeted plasma-based genotyping in metastatic breast cancer

Paul Makhlouf, A. Bardia, D. Juric, 2022, npj Breast Cancer.

Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network

Jeffrey W. Clark, Lauren L. Ritterhouse, M. Rivera, 2022, The oncologist.

Alpelisib for PIK3CA‐Mutated, Hormone Receptor–Positive Advanced Breast Cancer

H. Rugo, H. Iwata, D. Juric, 2019, The New England journal of medicine.

Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias.

Dejan Juric, D. Juric, B. Sikic, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-in-human, phase I, dose-escalation study of selective PI3K{alpha} isoform inhibitor MLN1117 in patients (pts) with advanced solid malignancies.

J. Nemunaitis, D. Juric, J. Bono, 2015 .

Abstract PD1-3: Ph1b study of the PI3K inhibitor GDC-0032 in combination with fulvestrant in patients with hormone receptor-positive advanced breast cancer

J. Baselga, T. Wilson, D. Juric, 2013 .

Data-driven discovery of targets for bipotent anticancer drugs identifies Estrogen Related Receptor Alpha

Clifford A. Meyer, Phillip B. Nicol, Jun Liu, 2021, bioRxiv.

Cell Atlas of The Human Fovea and Peripheral Retina

A. Regev, J. Sanes, K. Shekhar, 2020, bioRxiv.

TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma.

W. Hahn, G. Getz, A. Iafrate, 2019, Cancer discovery.

Altered interactions between circulating and tissue-resident CD8 T cells with the colonic mucosa define colitis associated with immune checkpoint inhibitors

Linda T. Nieman, N. Hacohen, A. Villani, 2021, bioRxiv.

Detection of Novel Actionable Genetic Changes in Salivary Duct Carcinoma Helps Direct Patient Treatment

Julie M. Batten, A. Iafrate, K. Flaherty, 2012, Clinical Cancer Research.

Deep learning enables genetic analysis of the human thoracic aorta

A. Philippakis, E. Benjamin, P. Ellinor, 2021, Nature Genetics.

Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.

Dejan Juric, Jordi Rodon, Alan Huang, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets

Timothy L. Tickle, Samouil L. Farhi, Pardis C Sabeti, 2021, Nature.

Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor

C. Schnell, D. Juric, J. Harding, 2018, Investigational New Drugs.

Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics

Kyle J. Gaulton, David S. Fischer, Malte D. Luecken, 2021, Nature Medicine.

PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1

Carlotta Costa, Mari Mino-Kenudson, Dejan Juric, 2013, Proceedings of the National Academy of Sciences.

Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation.

R. Heist, D. Juric, J. Lennerz, 2021, Cancer discovery.

AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.

Angela Tam, Manway Liu, J. Baselga, 2015, Cancer cell.

A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer

D. Juric, G. Curigliano, J. Huober, 2021, Clinical Cancer Research.

Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies.

D. Juric, M. Boehm, C. Quadt, 2014, British journal of clinical pharmacology.

Overall survival of CDK4/6-inhibitors-based treatments in clinically relevant subgroups of metastatic breast cancer: systematic review and meta-analysis.

L. Pusztai, D. Juric, F. Puglisi, 2020, Journal of the National Cancer Institute.

Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity.

Sarah A. Boswell, P. Sorger, R. Everley, 2019, Cell chemical biology.

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer.

B. Taylor, S. Loi, S. Chandarlapaty, 2019, Cancer discovery.

Cell atlas of aqueous humor outflow pathways in eyes of humans and four model species provides insight into glaucoma pathogenesis

A. Regev, J. Sanes, K. Shekhar, 2020, Proceedings of the National Academy of Sciences.

A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

J. Baselga, Y. Bang, R. Salgia, 2017, BMC Cancer.

Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer

Ben S. Wittner, B. Wittner, M. Lawrence, 2019, npj Precision Oncology.

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.

J. Lehár, Manway Liu, R. Schlegel, 2014, Cancer cell.

Phase 1 results of a phase 1/2 trial of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination, in patients with advanced solid and hematologic cancers.

R. Advani, D. Siegel, D. Juric, 2022, Journal of Clinical Oncology.

A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies

Keisuke Kuida, Dejan Juric, Serap Sankoh, 2017, Clinical Cancer Research.

Phase I trial of the PI3Kα isoform inhibitor TAK-117

J. Nemunaitis, D. Juric, E. Heath, 2017 .

A First-inHuman , Phase I , Dose-Escalation Study of TAK-117 , a Selective PI 3 Kα Isoform Inhibitor , in Patients with Advanced Solid Malignancies

J. Nemunaitis, D. Juric, E. Heath, 2017 .

Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer

W. Winckler, R. Leary, Bernard Pereira, 2021, Nature communications.

First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety

T. Burns, D. Juric, R. Yaeger, 2022, Journal of Clinical Oncology.

Temporal and Spatial Heterogeneity of Host Response to SARS-CoV-2 Pulmonary Infection

Linda T. Nieman, N. Hacohen, M. Rivera, 2020, medRxiv.

A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR

A. Tolcher, G. Shapiro, D. Juric, 2020, Investigational New Drugs.

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors

A. Jimeno, M. Hidalgo, J. Baselga, 2015, Clinical Cancer Research.

Circulating tumor cells exhibit metastatic tropism and reveal brain metastasis drivers.

J. Hicks, A. Bardia, D. Juric, 2019, Cancer discovery.

Safety, pharmacokinetics, and preliminary activity of the alpha-specific PI3K inhibitor BYL719: Results from the first-in-human study.

J. Berlin, J. Baselga, D. Juric, 2013 .

Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer

Borivoj Vojnovic, Dejan Juric, Charles M. Perou, 2014, Science Signaling.

Regional activation of chromosomal arm 7q with and without gene amplification in taxane‐selected human ovarian cancer cell lines

D. Juric, B. Sikic, Kevin G. Chen, 2006, Genes, chromosomes & cancer.

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers

T. Wilson, D. Juric, Matthew T. Chang, 2020, Clinical Cancer Research.

High-Content Biopsies Facilitate Molecular Analyses and Do Not Increase Complication Rates in Patients With Advanced Solid Tumors.

R. Weissleder, M. Mino‐Kenudson, J. Engelman, 2017, JCO precision oncology.

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.

Gad Getz, Ignaty Leshchiner, Dejan Juric, 2017, Cancer discovery.

Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. CANCER

G. Getz, A. Iafrate, P. Furet, 2022 .

Amplification of whole tumor genomes and gene-by-gene mapping of genomic aberrations from limited sources of fresh-frozen and paraffin-embedded DNA.

J. Pollack, L. Recht, H. Vogel, 2005, The Journal of molecular diagnostics : JMD.

MYC-Interacting Genes in Human Gliomas Gliomagenesis Pathway Maps and Three Novel Functional Network Analysis Reveals Extended

L. Recht, H. Vogel, M. Bredel, 2005 .

Tumor Necrosis Factor-α–Induced Protein 3 As a Putative Regulator of Nuclear Factor-κB–Mediated Resistance to O6-Alkylating Agents in Human Glioblastomas

L. Recht, H. Vogel, M. Bredel, 2006 .

Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas.

L. Recht, H. Vogel, M. Bredel, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers

Jeffrey W. Clark, T. Golub, G. Getz, 2019, Nature Medicine.

Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition

M. Lawrence, M. Mino‐Kenudson, A. Shaw, 2020, npj Precision Oncology.

mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer

N. Rosen, Manway Liu, J. Baselga, 2013, Science Translational Medicine.

Elkabets-Mutant Breast Cancer PIK 3 CA Inhibitors in α mTORC 1 Inhibition Is Required for Sensitivity to PI 3 K p 110

Manway Liu, J. Baselga, M. Mino‐Kenudson, 2013 .

Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line.

T. Fojo, T. Ried, D. Juric, 2005, Cancer Research.

Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer

A. Bardia, D. Juric, S. Goel, 2021, NPJ breast cancer.

First‐in‐human trial of the PI3Kβ‐selective inhibitor SAR260301 in patients with advanced solid tumors

Dejan Juric, Keith T Flaherty, Michael A Davies, 2018, Cancer.

Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance

J. Baselga, D. Juric, U. Mahmood, 2016, The Journal of Nuclear Medicine.

Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience.

A. Niemierko, A. Bardia, A. Kambadakone, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer

G. Getz, A. Bardia, A. Kambadakone, 2021, Cancer discovery.

Vascular smooth muscle cell phenotype switching in carotid atherosclerosis

P. Ellinor, E. Isselbacher, D. Juric, 2021, JVS-vascular science.

A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors.

J. Desai, D. Juric, J. Soria, 2014 .

Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer

W. Winckler, R. Leary, Bernard Pereira, 2021, Nature Communications.

Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYL

P. Neven, H. Rugo, Yeon-Hee Park, 2020 .

A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC).

A. Niemierko, A. Bardia, A. Kambadakone, 2019, Journal of Clinical Oncology.

Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer

G. Getz, M. Lawrence, A. Iafrate, 2020, Clinical Cancer Research.

PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Kα inhibitors in breast cancer.

M. Mino‐Kenudson, J. Engelman, C. Benes, 2019, Cancer discovery.

Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53

B. Nahed, A. Bardia, D. Juric, 2023, The oncologist.

Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2- metastatic breast cancer (mBC).

A. Bardia, D. Juric, J. Diamond, 2018 .

Differential Gene Expression Patterns and Interaction Networks in BCR/ABL Positive and Negative Adult Acute Lymphoblastic Leukemias.

D. Juric, B. Sikic, P. O'dwyer, 2006 .

Multi-Omics Profiling Establishes the Polypharmacology of FDA Approved CSK4/6 Inhibitors and Its Impact on Drug Response

Sarah A. Boswell, P. Sorger, R. Everley, 2018 .

Therapeutically advantageous secondary targets of abemaciclib identified by multi-omics profiling of CDK4/6 inhibitors

Sarah A. Boswell, P. Sorger, R. Everley, 2017 .

A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types

C. Benes, D. Juric, H. Willers, 2018, Breast Cancer Research and Treatment.

Comparison of tissue genotyping (TG) vs circulating tumor DNA (ctDNA) for selection of matched therapy and impact on clinical outcomes among patients with metastatic breast cancer (MBC).

Dejan Juric, Andrzej Niemierko, Beverly Moy, 2018 .

Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer

A. Iafrate, A. Bardia, D. Juric, 2022, Therapeutic advances in medical oncology.

Abstract PD8-06: Phase I/II trial of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer

M. Korpal, D. Juric, A. Cohen, 2021 .

Abstract PS11-26: A phase 1 study of D-0502, an orally bioavailable SERD, for advanced or metastatic HR-positive and HER2-negative breast cancer

D. Juric, Bing-he Xu, Yaolin Wang, 2021 .

Abstract PD4-02: Advantageous polypharmacology of abemaciclib revealed by omics profiling of CDK4/6 inhibitors

Sarah A. Boswell, P. Sorger, R. Everley, 2018 .

Abstract GS1-05: Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study

A. Tolcher, A. Bardia, T. Mukohara, 2022, Cancer Research.

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.

J. Baselga, T. Wilson, J. Ware, 2017, Cancer discovery.

A single-cell and spatial atlas of autopsy tissues reveals pathology and cellular targets of SARS-CoV-2

Timothy L. Tickle, Samouil L. Farhi, Daniel T. Montoro, 2021, bioRxiv.

Cell atlas of aqueous humor outflow pathways in eyes of humans and four model species provides insight into glaucoma pathogenesis

A. Regev, J. Sanes, K. Shekhar, 2020, Proceedings of the National Academy of Sciences.

Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

C. Sotiriou, I. Bièche, D. Juric, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer.

T. Burns, D. Juric, M. Schuler, 2022, The New England journal of medicine.

Abstract LB-327: Loss of PTEN leads to clinical resistance to the PI3Kα inhibitor BYL719 and provides evidence of convergent evolution under selective therapeutic pressure

Benjamin J. Ainscough, E. Mardis, O. Griffith, 2014 .

Phase I Dose Escalation Study of Taselisib (GDC-0032), an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors

Sandra, J. Baselga, T. Wilson, 2017 .

Targeting TBK1 to overcome resistance to cancer immunotherapy

N. Hacohen, A. Giobbie-Hurder, P. Sorger, 2022, Nature.

LBA4 Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase I trial

A. Tolcher, A. Bardia, Toshio Shimizu, 2021 .

Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer.

A. Iafrate, A. Niemierko, A. Bardia, 2020, JCO precision oncology.

Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer

A. Niemierko, A. Bardia, D. Juric, 2023, NPJ breast cancer.

Abstract PD13-05: Alpelisib + fulvestrant in patients with PIK3CA-mutated, HR+, HER2— advanced breast cancer (ABC) who received chemotherapy or endocrine therapy (ET) as immediate prior treatment: BYLieve Cohort C primary results and exploratory biomarker analyses

P. Neven, H. Rugo, Yeon-Hee Park, 2022, Cancer Research.

Abstract P1-17-10: H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer - A phase II study

M. Korpal, D. Juric, A. Cohen, 2022, Cancer Research.

Phase 1b study of H3B-6545 in combination with palbociclib in women with metastatic estrogen receptor–positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer.

M. Korpal, D. Juric, J. Pipas, 2021 .

Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.

M. Korpal, D. Juric, S. Johnston, 2021 .

Abstract PS12-23: Development of H3B-6545, a first-in-class oral selective ER covalent antagonist (SERCA), for the treatment of ERaWTand ERaMUTbreast cancer

M. Hao, M. Warmuth, M. Korpal, 2021 .

Abstract CT109: A phase I/Ib study evaluating GDC-0077 plus fulvestrant in patients withPIK3CA-mutant, hormone receptor-positive/HER2-negative breast cancer

K. Hutchinson, D. Juric, A. Italiano, 2020 .

Abstract P1-19-46: A phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (L) with and without palbociclib (P) in patients withPIK3CA-mutant HR+/HER2- breast cancer

K. Hutchinson, D. Juric, A. Italiano, 2020 .

The Genetic Determinants of Aortic Distension

A. Philippakis, P. Ellinor, Kenney Ng, 2021, medRxiv.

Evaluation of tolerability and anti-tumor activity of GDC-0032, a PI3K inhibitor with enhanced activity against PIK3CA mutant tumors, administered-to patients with advanced solid tumors

J. Baselga, T. Wilson, D. Juric, 2013 .

Abstract CT046: A phase I basket study of the PI3K inhibitor taselisib (GDC-0032) inPIK3CA-mutated locally advanced or metastatic solid tumors

J. Baselga, T. Wilson, D. Juric, 2018, Clinical Trials.

SOLAR-1: A phase III study of alpelisib + fulvestrant in men and postmenopausal women with HR+/HER2– advanced breast cancer (BC) progressing on or after prior aromatase inhibitor therapy.

H. Rugo, H. Iwata, D. Juric, 2016 .

Association between PIK3CA mutation status and development of brain metastases in HR+/HER2- metastatic breast cancer

A. Iafrate, P. Brastianos, A. Bardia, 2019, Annals of Oncology.

Abstract OT-03-02: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors

Michael N. Alonso, E. Perez, D. Juric, 2021 .

Abstract PD2-07: Alpelisib + letrozole in patients withPIK3CA-mutated, hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) previously treated with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + fulvestrant: BYLieve study result

H. Rugo, D. Juric, S. Chia, 2021 .

A phase 3 study of alpelisib (ALP) plus fulvestrant (FUL) in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) ABC progressing on or after aromatase inhibitor (AI) therapy: SOLAR-1.

H. Rugo, H. Iwata, D. Juric, 2017 .

Identifying Early-Phase Clinical Trial Participants at Risk for Experiencing Worse Clinical Outcomes

D. Juric, N. Horick, R. Nipp, 2023, JCO oncology practice.

Phase Ib Study of the Histone Deacetylase 6 Inhibitor Citarinostat in Combination With Paclitaxel in Patients With Advanced Solid Tumors

G. Shapiro, D. Juric, C. Dumitru, 2022, Frontiers in Oncology.

Abstract PD5-5: Phase I study of the PI3Kα inhibitor BYL719 plus fulvestrant in patients withPIK3CA-altered and wild type ER+/HER2- locally advanced or metastatic breast cancer

E. Winer, J. Berlin, J. Baselga, 2015 .

Erratum for the research article: mTORC1 inhibition is required forsensitivity to PI3K p110a inhibitors in PIK3CA-mutant breast cancer (Science Translational Medicine DOI: 10.1126/scitranslmed.3005747)

Manway Liu, J. Baselga, M. Mino‐Kenudson, 2018 .

A phase I open label study evaluating VT1021 in patients with advanced solid tumors.

D. Juric, A. Bullock, A. Patnaik, 2019, Journal of Clinical Oncology.

Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha

Clifford A. Meyer, Phillip B. Nicol, Jun Liu, 2022, Cancer discovery.

Abstract P4-22-18: Phase Ib safety, efficacy, and molecular analysis of ribociclib (LEE011) plus letrozole for the treatment of ER+, HER2– advanced breast cancer

D. Juric, A. Wardley, P. Munster, 2017 .

Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2–) advanced breast cancer (aBC): Phase Ib safety, preliminary efficacy and molecular analysis.

D. Juric, M. Campone, P. Munster, 2016 .

Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results.

H. Rugo, D. Juric, S. Chia, 2019, Journal of Clinical Oncology.

Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer From SOLAR-1

Xiaolei Zhou, H. Rugo, H. Iwata, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours

Jeffrey W. Clark, R. Sullivan, K. Flaherty, 2019, Annals of Oncology.

A phase 1b study of the safety, pharmacokinetics, and preliminary antitumor activity of citarinostat (ACY-241) in combination with paclitaxel (Pac) in patients (pts) with advanced solid tumors (AST).

G. Shapiro, D. Juric, Peng-Yu Chen, 2018 .

Trial design of a first-in-human phase 1 evaluation of SY-1365, a first-in-class selective CDK7 inhibitor, with initial expansions in ovarian and breast cancer.

A. Tolcher, G. Shapiro, D. Juric, 2018 .

A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression.

Maristela L Onozato, A. Iafrate, A. Niemierko, 2023, JCO precision oncology.

LBA1 Interim results of a phase I/Ib study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib (RIB) or alpelisib (ALP) in patients with ER+ breast cancer (BC) who had progressed after endocrine therapy (ET)

D. Juric, G. Curigliano, S. Cresta, 2020 .

Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer

A. Bardia, D. Juric, S. Goel, 2021, npj Breast Cancer.

Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Biomarker (BM) analyses by next-generation sequencing (NGS) from the SOLAR-1 study.

H. Rugo, H. Iwata, D. Juric, 2022, Journal of Clinical Oncology.

First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737).

K. Flaherty, G. Shapiro, D. Juric, 2015 .

Abstract PD1-13: Somatic BRCA mutation detection by circulating tumor DNA analysis in patients with metastatic breast cancer: Incidence and association with tumor genotyping results, germline BRCA mutation status, and clinical outcomes

A. Niemierko, A. Bardia, D. Juric, 2018 .

Abstract P2-16-14: Preliminary safety, pharmacokinetics and anti-tumor activity of BYL719, an alpha-specific PI3K inhibitor in combination with fulvestrant: Results from a phase I study

J. Berlin, J. Baselga, D. Juric, 2013 .

Author Correction: Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers

Jeffrey W. Clark, T. Golub, G. Getz, 2019, Nature Medicine.

Single-cell profiling of human heart and blood in immune checkpoint inhibitor-associated myocarditis.

A. Villani, M. Mino‐Kenudson, G. Boland, 2022, Journal of Clinical Oncology.

Incidence of peripheral edema in patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancer

A. Bardia, A. Taghian, D. Juric, 2019, Breast Cancer Research and Treatment.

518MO Tolerability and preliminary clinical activity of SY-5609, a highly potent and selective oral CDK7 inhibitor, in patients with advanced solid tumors

G. Shapiro, D. Juric, G. Hodgson, 2021, Annals of Oncology.

Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers

B. Taylor, M. Berger, A. Drilon, 2019, Nature.

High-resolution genome-wide mapping of genetic alterations in human glial brain tumors.

L. Recht, H. Vogel, M. Bredel, 2005, Cancer research.

476 First-in-human phase 1/2 study of the first-in-class SUMO-activating enzyme inhibitor TAK-981 in patients with advanced or metastatic solid tumors or relapsed/refractory lymphoma: phase 1 results

D. Juric, A. Berger, A. Dowlati, 2021, Journal for ImmunoTherapy of Cancer.

Immune Responses in Checkpoint Myocarditis Across Heart, Blood, and Tumor

Linda T. Nieman, A. Villani, G. Boland, 2023, bioRxiv.

Phase Ib trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy and a CDK4/6 inhibitor for patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) (TAKTIC).

A. Bardia, D. Juric, L. Ellisen, 2020 .

Targeting TBK1 to overcome resistance to cancer immunotherapy

N. Hacohen, A. Giobbie-Hurder, P. Sorger, 2023, Nature.

A phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual-action antibody, in patients (pts) with refractory/recurrent epithelial tumors: Expansion cohorts.

A. Jimeno, M. Hidalgo, J. Baselga, 2012 .

Incidence of peripheral edema in patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancer

A. Bardia, A. Taghian, D. Juric, 2019, Breast Cancer Research and Treatment.

The Genetic Determinants of Aortic Distention.

A. Philippakis, P. Ellinor, D. Juric, 2023, Journal of the American College of Cardiology.

Multi-omics profiling establishes the polypharmacology of FDA Approved CDK4/6 inhibitors and its impact on drug response

Sarah A. Boswell, P. Sorger, R. Everley, 2017, bioRxiv.

Deep learning enables genetic analysis of the human thoracic aorta

A. Philippakis, E. Benjamin, P. Ellinor, 2020, Nature Genetics.

A phase 1 study of LJM716 in patients with esophageal squamous cell carcinoma, head and neck cancer, or HER2-overexpressing metastatic breast or gastric cancer.

J. Baselga, Y. Bang, D. Juric, 2014 .

Abstract PD13-08: PD13-08 Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/HER2–Negative Breast Cancer (BC)

A. Bardia, T. Mukohara, D. Juric, 2023, Cancer Research.

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.

A. Tolcher, T. Mukohara, D. Juric, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias.

D. Juric, B. Sikic, P. O'dwyer, 2006, Journal of Clinical Oncology.

Abstract P1-18-22: AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigation

D. Haber, A. Bardia, S. Maheswaran, 2022, Cancer Research.

The glutathione S-transferase Gstt1 drives survival and dissemination in metastases.

G. Wojtkiewicz, D. Juric, R. Mostoslavsky, 2024, Nature cell biology.

Immune Responses in Checkpoint Myocarditis Across Heart, Blood, and Tumor

Linda T. Nieman, A. Villani, G. Boland, 2023, bioRxiv.

1254 Distinguishing T-cell responses in paired heart and tumor samples from patients with immune checkpoint-related myocarditis

M. Mino‐Kenudson, G. Boland, D. Juric, 2022, Regular and Young Investigator Award Abstracts.

J. Baselga, Y. Bang, R. Salgia, 2017, BMC Cancer.

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.

J. Baselga, J. Ware, D. Juric, 2017, Cancer discovery.

Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer.

D. Juric, Martha Donoghue, L. Marshall, 2024, European journal of cancer.

Abstract 2638: Sacituzumab Govitecan, combination with PARP inhibitor, Talazoparib, in metastatic triple-negative breast cancer (TNBC): Translational investigation

A. Niemierko, A. Bardia, D. Juric, 2022, Cancer Research.

The Right Dose: Results of a Patient Advocate-Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life.

M. Burkard, H. Rugo, D. Juric, 2024, JCO oncology practice.

Abstract P3-14-01: Phase Ib/II study of ribociclib and alpelisib and letrozole in ER+, HER2– breast cancer: Safety, preliminary efficacy and molecular analysis

D. Juric, M. Campone, P. Munster, 2016 .

Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique

G. Hortobagyi, D. Juric, T. Pluard, 2024, NPJ breast cancer.